Amid the complexity and expense of the small-molecule drug discovery process, from identification and validation of a “drugable” target to the development of an understanding of the impact of pharmacogenomic differences in patient populations on drug action, lies the “hit-to-lead” process in which compounds that show activity in an assay system are iteratively improved upon through medicinal chemistry that is guided by more detailed assays and filtering criteria.